Global
Ventilator-Associated Pneumonia Market Research Report: Information by
Diagnosis (Clinical, Radiological, Microbiological, and Others), End User (Hospitals
& Clinics, Research & Academic Institutes, Ambulatory Care Centers, and
Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East
& Africa)—Forecast till 2025
Market
Scenario
According
to CDC in 2013, there were 2.8 million traumatic brain injury visits to
emergency department and hospitals. The emergency department visits of brain
injury patients increased by 47% from 2007. Thus, increasing incidence of TBI
drives the growth of the market. Furthermore, increasing geriatric population
is likely to fuel the market to grow.
According to the U.S. Census Bureau in 2015, 47.8 million people were 65
years or older, and in 2060, 98.2 million are expected to be 65 years or
older. Such increasing trend in the
geriatric population provides favorable backgrounds for the market to grow.
Ventilator-associated
pneumonia is a type of lung infection caused to patients who are on
ventilators. Ventilator-associated pneumonia is caused mainly due to lung
disease, neurologic disease, and trauma to critically ill persons. Diagnosing
VAP requires aggressive surveillance combined with the radiographic
examination, bedside examination, and microbiologic examinations of respiratory
secretions. Growing Intensive Care Unit Admissions due to rising prevalence of
respiratory diseases, rising number of ICU beds and high incidence of traumatic
injuries provides favorable backgrounds for the market to grow.
However,
factors such as expensive diagnostic tests, high ventilator charges, inappropriate
reimbursement scenario, risks associated with ventilators are expected to
restrict the market growth during the forecast period.
Key players
Some of the
key players for the global Ventilator-associated
pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS
(Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria)
and other.
Segmentation
The global
Ventilator-associated pneumonia market is segmented on the basis of diagnosis,
mode of treatment, and end-user. The Ventilator-associated pneumonia market, by
diagnosis categorized into Clinical Examination, Radiological Examination,
Microbiological Analysis and others. Microbiological Analysis is further
sub-segmented into Blood and pleural fluid cultures, Nonquantitative or
semi-quantitative airway sampling and Quantitative cultures of airway
specimens. Mode of treatment segment is segmented into Homecare, Hospital care,
and others. On the basis of end-user, the market is segmented into Hospitals
& Clinics, Research centers, Ambulatory Care Centers and Emergency Medical
Services (EMS).
Regional Market Summary
The Ventilator-associated
pneumonia market is dominated by North America owing to the rising geriatric
population within the region. The U.S. Census Bureau projected that in 2060,
19.7 million would be of age 85 or older. This influences the growth of this market
in this region.
Asia Pacific
was projected to be the fastest growing region for the global
Ventilator-associated pneumonia market in 2017. The rising geriatric
population, increasing healthcare expenditure and growing respiratory disorders
in Asia is expected to drive market growth in this region. According to The
Asian Development Bank (ADB), the geriatric population in Asia is estimated to
reach 923 million by 2050. Thus, this provides favorable backgrounds for the
Ventilator-associated pneumonia market to grow.
It is
estimated that Europe stood second in the global Ventilator-associated
pneumonia market owing to increasing prevalence of lung diseases. According to
European respiratory society, more than 50% of deaths are due to lung diseases.
Thus, increasing prevalence of lung diseases in this region influences the
growth of this market in this region.
The Middle
East and Africa holds the least share in the global Ventilator-associated
pneumonia market due to the presence of stringent government policies, poor
economies, under-developed healthcare infrastructure and low penetration of
healthcare services, especially within the African region.
Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report